Roemerine

Roemerine

SCHEMBL678048

CN1CCc2cc3c(c4c2[C@@H]1Cc1ccccc1-4)OCO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 1.00
POLB P06746 3/20 1.00
CASP6 P55212 2/20 1.00
KMT2A Q03164 2/20 1.00
MEN1 O00255 1/20 1.00
APAF1 O14727 1/20 1.00
GAA P10253 1/20 1.00
RAB9A P51151 1/20 1.00
CASP7 P55210 1/20 1.00
DYRK1A Q13627 1/20 1.00
ADRA1D P25100 1/20 1.00
ADRA1A P35348 1/20 1.00
ADRA1B P35368 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
BCHE P06276 1/20 0.73
ACHE P22303 1/20 0.73
KDM4E B2RXH2 3/20 0.71
LMNA P02545 3/20 0.71
MAPT P10636 2/20 0.71
TYR P14679 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Roemerine SCHEMBL30047645 1.00 DRD2 (1.00) DRD2POLBCASP6KMT2AMEN1
Roemerine SCHEMBL30047807 1.00 DRD2 (1.00) DRD2POLBCASP6KMT2AMEN1
Roemerine SCHEMBL673805 1.00 DRD2 (1.00) DRD2POLBCASP6KMT2AMEN1
Roemerine SCHEMBL17906539 1.00 DRD2 (1.00) DRD2POLBCASP6KMT2AMEN1
Neolitsine SCHEMBL31029789 0.88 POLB (0.81) DRD2POLBCASP6KMT2AMEN1
SCHEMBL10941634 0.86 DRD2 (0.76) DRD2POLBCASP6KMT2AMEN1
SCHEMBL10750734 0.86 DRD2 (0.76) DRD2POLBCASP6KMT2AMEN1
SCHEMBL11249155 0.85 DRD2 (0.74) DRD2POLBCASP6KMT2AMEN1
SCHEMBL11249690 0.85 DRD2 (0.76) DRD2POLBCASP6KMT2AMEN1
Isolaureline SCHEMBL29761843 0.85 BCHE (1.00) DRD2POLBCASP6KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0257887-A2 Ophthalmic compositions HOUSTON BIOTECHNOLOGY INCORPORATED (US) 1988-03-02 EP claimed
US-20130023487-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2013-01-24 US disclosed
US-20130023487-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2013-01-24 US disclosed
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2012-07-26 US disclosed
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2012-07-26 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
EP-0257887-A2 Ophthalmic compositions HOUSTON BIOTECHNOLOGY INCORPORATED (US) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION RPN2, LSS, CLIC4 DRD2 252/4885POLB 1879/4885CASP6 508/4885
US-20130023487-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION RPN2, LSS, CLIC4 DRD2 252/4885POLB 1879/4885CASP6 508/4885
US-20090069277-A1 Compounds and compositions for treating infection RPN2, LSS, CLIC4 DRD2 252/4885POLB 1879/4885CASP6 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.